Insmed Inc

Insmed is a commercial-stage biopharmaceutical company focused on respiratory, inflammatory, pulmonary, and rare disease treatments, with an approved portfolio that includes Brinsupri and Arikayce. The company’s opportunity is tied to expanding adoption of its commercial products while advancing a pipeline aimed at areas of meaningful unmet medical need. During the quarter, shares detracted from performance despite headline results that were generally better than expected, as investors focused on early launch dynamics for Brinsupri. Concerns centered on patient additions, discontinuation rates, and compliance trends, which raised questions about the quality and durability of the launch. While these issues pressured the stock, management has begun providing greater detail around launch dynamics, and we believe improved execution and additional data could help restore investor confidence over time.

Insmed Incorporated is a biotechnology company with three lead pulmonology assets that we believe can collectively generate more than $8 billion in peak sales. We are particularly excited about Brinsupri for non-cystic fibrosis bronchiectasis, which we view as a $5 billion-plus opportunity. Despite a strong start to the launch, shares fell after first-quarter Brinsupri sales missed expectations due to early signs of higher treatment discontinuations. Long term, we continue to view Brinsupri as an important treatment option for the 500,000-plus bronchiectasis patients in the U.S. We remain bullish on the portfolio's long-term fundamentals, including the opportunity for treprostinil palmitil inhalation powder (TPIP), which is being studied for pulmonary arterial hypertension.

Insmed is a commercial-stage biotechnology company focused on pulmonary diseases. BRINSUPRI® continued its rapid launch, with robust patient uptake and encouraging third-party data. While Q1 sales came in modestly below elevated investor expectations, reflecting concerns around discontinuation rates, continuation on therapy and typical early-year seasonality, the underlying launch trajectory remains encouraging. We continue to view BRINSUPRI® as a significant long-term opportunity. Our due diligence suggests the therapy remains well tolerated and is on track to achieve blockbuster-level sales.

Insmed is a commercial-stage biotechnology company focused on pulmonary diseases. Brinsupri® continued its rapid launch. While patient uptake remains strong, Q1 sales fell short of elevated investor expectations, raising questions about discontinuation rates and putting downward pressure on the stock. However, we continue to view Brinsupri® as a meaningful long-term opportunity. Our due diligence suggests the drug remains well tolerated and is on track for blockbuster-level sales.

Long-standing biotech holding Insmed gave up some of the prior year’s strength driven by concerns around the pace of key drug Brinsupri’s launch. We remain confident in the meaningful long-term peak sales potential and believe recent weakness has been overly punitive.

We added Insmed, a biotechnology company focused on respiratory diseases, where multiple approved potential blockbuster drugs and an attractive clinical pipeline create meaningful long-term growth potential at an attractive price.

Insmed, a biotechnology company focused on pulmonary diseases, continues to execute well. Its lead product, ARIKAYCE®, continues to perform well, with steady commercial growth and durable demand providing a stable revenue base. Early launch data for Brinsupri™ indicate patient uptake and prescriber adoption are tracking ahead of expectations, further derisking the commercial opportunity. Management has highlighted strong demand alongside manageable near-term payer dynamics. We are encouraged by the company’s execution and believe Brinsupri™ has the potential to drive a meaningful profit cycle in the coming quarters and years. We added to the position amid industry volatility.

Insmed has achieved a major milestone with the recent FDA approval of brensocatib (brand name: BRINSUPRI) for bronchiectasis, marking the first approved therapeutic option for this chronic lung disease. We anticipate a rapid adoption curve that should push the company toward sustained profitability. Additionally, the second pipeline asset, TPIP, has achieved key clinical validation in pulmonary arterial hypertension and idiopathic pulmonary fibrosis, reinforcing its potential as a transformative therapy. Insmed is building a powerful respiratory disease franchise, and despite a recent rally, shares remain well below our estimate of their intrinsic value, leaving substantial room for multi-year appreciation.

Insmed contributed positively to the portfolio during a period where the index’s biotech industry gained approximately 22%, largely due to positive trial results, M&A and improving investor sentiment. The company delivered on positive data and commercial catalysts, indicating strong growth potential in the biotech sector. This performance reflects Insmed's ability to capitalize on favorable market conditions and its underlying business strengths.

Insmed Inc., a biopharmaceutical company focused on developing and commercializing therapies for patients with rare diseases, rallied 43%. Their Brinsupri received FDA approval as the first and only available treatment for non-cystic fibrosis bronchiectasis, a chronic lung disease. This approval positions Insmed favorably in the market, addressing a significant unmet need and potentially driving substantial revenue growth.